固定剂量达托霉素:金黄色葡萄球菌感染中PK/PD优化的机会
本研究前瞻性测试了肥胖和非肥胖成人固定剂量达托霉素750 mg的方案,并构建群体药代动力学模型,模拟固定剂量与按体重剂量方案达到疗效和毒性目标的概率。结果显示固定剂量在体重≤74 kg和>74 kg患者中暴露量相似,男性及肾功能增强需更高剂量,固定剂量方案肌酸磷酸激酶升高预测更低,但无经验性给药方案能同时达到≥90%疗效并最小化毒性风险,建议个体化治疗药物监测。
要点
- 固定剂量达托霉素750 mg在肥胖和非肥胖成人中暴露量相似。
- 男性和肾功能增强患者需更高固定或按体重剂量以达到疗效目标。
- 无经验性给药方案可同时达到≥90%疗效并最小化毒性,需考虑TDM。
核心结论
- 固定剂量达托霉素根据性别和肾功能调整,预期较按体重剂量改善疗效-毒性比、治疗转换和成本。
- 无经验性给药方案预测能同时达到≥90%疗效并最小化毒性风险,应考虑患者特异性治疗药物监测。
研究设计与样本
- 前瞻性测试固定剂量达托霉素750 mg在肥胖和非肥胖成人中的方案。
- 每例患者稳态时至少测量三次达托霉素浓度,构建群体药代动力学模型并模拟固定剂量(500-1000 mg)和按体重剂量(6-12 mg/kg)方案。
主要发现
- 固定剂量达托霉素750 mg在体重≤74 kg和>74 kg患者中中位AUC0-24分别为819 mg∙h/L和749 mg∙h/L。
- 男性及肾功能增强需更高固定和按体重剂量以达到疗效。
- 肌酸磷酸激酶升高见于2例患者(6.5%),预测固定剂量方案较按体重方案更低。
关键数值与推荐
- 疗效目标:24小时AUC0-24 ≥ 666 mg∙h/L。
- 毒性目标:最低浓度C min ≥24.3 mg/L。
临床怎么用
- 固定剂量达托霉素可根据性别和肾功能调整,以改善疗效-毒性比。
- 考虑患者特异性治疗药物监测以优化给药。
局限性
- 未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Daptomycin is a high-use intravenous antimicrobial agent affording the convenience of once-daily dosing. Prior studies suggest an opportunity to use a more operationally convenient fixed rather than weight-based dosing but this approach has not been studied prospectively. METHODS: This study quantified the probability of toxicity and efficacy end points by prospectively testing a fixed dose regimen of daptomycin (750 mg) in obese and non-obese adults. At least, three daptomycin concentrations were measured at steady-state for each patient. A population pharmacokinetic model was constructed to evaluate concentration-time profiles and investigate covariates of daptomycin clearance. Simulations were performed to evaluate the probability of achieving efficacy (24-h area under the curve (AUC0-24) ≥ 666 mg∙h/L) and toxicity (minimum concentration (C min) ≥24.3 mg/L) targets for fixed (500-1000 mg) and weight-based (6-12 mg/kg) daptomycin doses. RESULTS: Thirty-one patients (16 females, 15 males) with median (interquartile range (IQR)) age of 50 (30, 62) years and weight of 74 (54, 156) kg were included in the final analysis. Fixed dose daptomycin (750 mg) resulted in similar exposure across weights with a median (IQR) AUC0-24 of 819 (499, 1501) mg∙h/L and 749 (606, 1265) mg∙h/L in patients weighing ≤74 kg and >74 kg, respectively. Overall, male sex and increased kidney function necessitate higher fixed and weight-based doses to achieve efficacy. Creatine phosphokinase elevation was observed in two patients (6.5%) and predicted to be lower with fixed versus weight-based regimens. CONCLUSIONS: Fixed daptomycin dosing adjusted for sex and kidney function is expected to improve the efficacy-to-toxicity ratio, transitions of care, and costs compared to weight-based doses. However, no empiric dosing approach is predicted to achieve ≥90% efficacy while minimizing the risk of toxicity, so therapeutic drug monitoring should be considered on a patient-specific basis.
引用
- Olney KB, Pai MP, Thomas JK, et al. Fixed dose daptomycin: An opportunity for pharmacokinetic/pharmacodynamic optimization in Staphylococcus aureus infections. Pharmacotherapy. 2024. PMID: 39078247. doi:10.1002/phar.4602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。